# NCT04393350 (NCT04393350)

> Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

No report yet. It can be ordered.

- Drugs tested: lenvatinib plus pembrolizumab
- Indication: locally advanced nonmetastatic clear cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04393350
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Emory University
- Conditions: Kidney Cancer; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
- Interventions: Lenvatinib; Lenvatinib Mesylate; Pembrolizumab; Quality-of-Life Assessment; Questionnaire Administration
- Enrollment: 18
- Primary outcome: Objective Response Rate (Complete and Partial Responses)

## Indexed commentary on NCT04393350 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct04393350